Continuation rates of alpha-blockers mono-therapy in adult men, prescribed by urologists or general practitioners: a pharmacy-based study

The pharmacological treatment in male LUTS generally starts with α-blocker therapy [1‐3]. The Dutch general practitioner (GP) guideline “male LUTS” contains an advice to discontinue α-blocker therapy after 3–6 months of use [3]. This advice is based on the overall variable LUTS severity over time [4], but has no further evidence base. The guideline of Dutch urologists does not support this recommendation; neither does the guideline of the European Association of Urologists (EAU) [2]. In the latter, discontinuation of α-blockers is only suggested for men who receive combination treatment with a 5-α-reductase inhibitor [2].

Whether this difference in guideline advises leads to other prescription patterns between GPs and urologists has not been studied. We evaluated prescription patterns in the first year of α-blocker treatment in men initiated by Dutch GPs and urologists. We examined discontinuation rates as well as predictors for discontinuation in incident patients on α-blockers.

We identified 12,191 individual patients with one or more α-blocker prescriptions. In 5419 cases, urologists provided the first prescription. In the other 6772 cases (55.5%), GPs were the prescribers. Baseline characteristics are presented in Table 1.

The median treatment period for patients who started in the GPs office and in hospital was 210 days and 150 days, respectively. Figure 1 shows the number of current users at 2, 6, 13, 26 and 52 weeks for the complete sample. These numbers showed no relevant differences between the two prescriber groups (see supplementary file). Of all patients, 60.3% and 66.1% of, respectively, GP’s and urologists’ patients had discontinued treatment (Chi-square p < 0.001) within 1 year after initiating α-blocker treatment.

Discontinuation rates were age dependent with higher rates in the youngest age groups (see Table 2). At each point in time, we found the differences to be statistically significant (all Chi-square, p < 0.05).

Age, prescriber and year of first prescription were independent predictors of current use after 1 year of treatment in the multivariable logistic regression analysis (see Table 3). The percentage of explained variance for this model was 6.1% (Nagelkerke R²).

This pharmacy-based study shows that the majority of men who start an α-blocker discontinue its use within 1 year. In this respect, no clear differences are shown between patients with a first prescription from a GP or from a urologist. Only a minority of men who still use the α-blocker after 1 year have had a period of discontinuation.

The main limitation of this database study is that no clinical information is available from the patients and indications for prescriptions are not recorded which might have led to misclassification. Information was limited to patient age, date of prescription, and prescriber. In the Netherlands, α-blockers are also prescribed for stone expulsive therapy and in case of acute urinary retention to support trial without catheter [3]. The incidence of both problems is generally low, although especially urolithiasis might explain the high discontinuation rate after 6 weeks (50.9%) in the youngest age group.

Next, it is unclear if patients discontinued α-blocker use themselves, for example due to side effects or a lack of effectiveness, or if physicians actively gave the advice to stop its use. We expect that short-term use may especially be associated with lack of effect on symptom severity, side effects, or with other indications, such as urolithiasis. Previously, Koh et al. showed that resolved symptoms (31.1%), no symptom improvement (23.7%) and adverse events (20.0%) were the main reasons for discontinuation [6]. Another limitation may be the low percentage of explained variance of the regression model. This shows that other variables contribute to the treatment patterns, which were not taken into account in the analyses. In the American cohort study, the percentage of explained variance was not reported [7].

The main strength of this study is the large number of patients from whom information is available. This database is representative for the Netherlands [5]. Most patients in the Netherlands collect their prescriptions from a single pharmacist. α-Blockers are by no means available without a prescription. In the Netherlands, the pharmacists dispense each first prescription only for 2 weeks with an automated extension of this period based on the prescription. If patients did not understand that usage was meant for a longer period, this could explain part of the discontinuation after 2 weeks.

Although α-blockers are generally considered to be effective for the treatment of male LUTS, the discontinuation rate was high in this study, as well as in three other studies [6‐8]. In the first study, it was is unclear who was the first prescriber [8], whereas in the second study a combination of α-blocker and 5-α-reductase inhibitor prescriptions from a urologist was examined [6]. More recently, Rensing et al. showed in a large American cohort that discontinuation most frequently occurred in the first year after initiating treatment and resulted in a cumulative incidence of 53.1 (urologists) and 55.4% (PCPs) after 3 years [7]. For all prescriptions (α-blockers, 5ARI and anticholinergics), authors found a statistically significant difference in discontinuation rates between urologists and PCPs: hazard ratio 1.19 (CI 95% 1.09−1.29) [7]. We feel that this small difference is not clinically relevant.

A possible explanation of the high discontinuation in these and our studies may be that many men do not experience a clinically relevant effect, because LUTS have a multifactorial origin whilst α-blockers only influence one specific aspect [9, 10]. Although this is recognised in current guidelines, especially due to the low number of side effects and low costs of α-blockers, these drugs are advised for all men with uncomplicated LUTS who opt for active treatment.

Shortridge et al. showed much lower discontinuation rates, in a study using electronic medical records of 1807 patients with LUTS/BPH: 11.6% after 1 year [11]. This large difference may be explained by the inclusion criteria applied. To meet the inclusion criteria in that study, participants were required to have two or more prescriptions. So the high discontinuation rates in the first weeks of use, as shown in our study population, are excluded in that study. Finally, in the largest database on this topic, Cindolo et al. showed that the 1-year adherence in Italian men exposed to at least 6 months of mono-therapy or combination therapy [12]. The authors found that only 29% of these men adhered to therapy. We cannot explain the very large difference with our results. In men who used α-blockers for at least 6 months, 75% still used their medication after 1 year.

α-Blockers are the mainstay of pharmacological treatment of male LUTS. This is a “one size fits all” or “trial and error” strategy, focussing on one aspect of the male lower urinary tract. Defining subgroups of men with a higher chance of successful α-blocker treatment would serve patients and their physicians, and reduce the high discontinuation rates, simply by not initiating this treatment if the chance of success is low. As it is unlikely that new randomised controlled trials will be conducted for this drug group, observational studies based on real life practice may provide support for a more personalised approach.

We found a high discontinuation rate after 1 year of treatment, with about two-thirds of new patients discontinued treatment within 1 year. A period of discontinuation was seen in only 30% of patients who still used α-blockers 1 year after treatment initiation. Despite the differences between Dutch GP’s and urologist’s guidelines with respect to a discontinuation advice, the differences in (temporary) discontinuation rates described in this study are not clinically relevant.